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Thesis Summary
Heart failure (HF) is a progressive condition that occurs when one’s heart fails to meet
the oxygen demands of the body because it loses its efficiency in pumping blood. As such, HF
commonly manifests in people as shortness of breath, dizziness, or fatigue [2]. Two underlying
causes of HF are having high blood pressure (hypertension) and reduced elasticity of veins and
arteries (vascular stiffness) [18]. These conditions cause the left ventricle (LV), which pumps
oxygen-rich blood to the body, to be under intense pressure because it has to work harder to
deliver blood effectively. In this case, the LV gains muscle mass (hypertrophy, LVH) and
thickens, so the amount of space left for blood inside the ventricle is reduced [15]. Thus, when
the LV contracts, the ejection fraction (EF), which is the fraction of blood ejected out of the
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total volume of blood in the ventricle, is the same as it was when the patient had no symptoms
of HF (>45%) [11].
The condition where the EF is maintained, yet the patient has established HF is called
heart failure with a preserved ejection fraction (HFpEF) or diastolic heart failure [11]. Here, the
underlying issue in the LV that is promoting HF symptoms is its inability to relax and fill
efficiently (in part, due to the hypertrophy). This is reflected in parameters of HFpEF that are
quantified with echocardiography, such as LV mass, E/A ratio (Doppler velocities: Early-E/ late
atrial-A), or left atrial (LA) area. LV mass directly quantifies the amount of hypertrophy in the
LV, which increases as HFpEF develops. The E/A ratio is a measure of LV filling patterns, which
are disrupted with HFpEF: in a healthy heart, during early diastole (E), a consistent proportion
of blood flows from the LA to the LV prior to the opening of the mitral valve between the two
reservoirs, and then in late diastole (A) the LA contracts, the mitral valve opens, and the
remaining blood in the LA is actively squeezed into the LV. In established HFpEF, most of the LV
is already filled up by the time the LA contracts, thereby increasing the E/A ratio. Consequently,
the size of the LA has to increase to compensate for the increased pressure in the chamber.
Clinically, a patient’s LA area is measured as an indicator of HFpEF severity [5]. However,
there is not a clearly defined threshold of LA size that determines the need for someone to be
hospitalized. This is because there is so much variation from person to person in demographics,
genetics, and lifestyle which all affect their rate of HFpEF progression and threshold of when an
acute cardiovascular event will occur for them. These factors are the underlying reasons why
measuring the LA area at a single time point is not sufficient to provide a prognosis for a
patient. Since there are no medications or effective treatment options for HFpEF patients [2],
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there is a substantial need for both therapeutics and disease modeling in order to begin
treating patients and predicting the development of their disease without any lifestyle
interventions. Ultimately, this thesis project aims to determine the usefulness in measuring the
rate of LA dilation in animals with early HFpEF, in hopes that a predictive regression model
could prove to be more valuable than just taking a one-time measure of a patients’ LA area.
To that end, we employed a pre-clinical model with features mimicking HFpEF in mice.
Repeat echocardiographs of the LA area were taken prior to a left ventricular pressure overload
(LVPO) procedure, as well as 14 and 28 days afterwards. The data reveal that for both
genotypes used in the study, a predictive regression can be used to estimate LA size at any
subsequent day in the mouse’s trajectory according to a baseline LA measurement. This
modeling offers a prognosis for HFpEF development in mice, and holds potential to be
translated to humans after specific adjustments are accounted for.
Introduction
The rate of HF in the United States continues to increase every year, and is now
considered the leading cause of morbidity and mortality. Though researchers have made
significant progress in developing therapeutics for diseases like cancer, little progress has been
made in this realm for HF [4]. This is partly because of the assumed homogeneity of heart
disease. However, two distinct etiologies of HF have been identified. Though they both present
similar symptoms such as shortness of breath and fluid accumulation, each type responds
differently to therapeutics, and they have varying results in clinical outcomes [2]. The main
difference between the two etiologies is whether or not the EF is reduced. When the EF of the
LV is less than 45%, the patient has heart failure with a reduced ejection fraction (HFrEF). On
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the other hand, when HF symptoms are present and the EF is greater than 45%, the patient has
heart failure with a preserved ejection fraction (HFpEF) [11].
Of the nearly 6 million patients with HF in the United States, at least half of them have
HFpEF [6]. There have been therapeutics and device-driven therapies that have significantly
improved the clinical outcomes for patients with HFrEF. No such therapies have been identified
for HFpEF, resulting in 50% of patients with HF not having effective treatment options [2]. HFpEF
is closely associated with aging, in that it is most common in the elderly population. This is
because the diastolic dysfunction underlying HFpEF develops secondary to hypertension and
vascular stiffness, which both increase with age [18]. Due to the intense strain on the LV in these
conditions, the LV undergoes myocardial remodeling: It increases in mass (hypertrophy; LVH),
and its extracellular matrix (ECM) profile changes [15]. Ultimately, these myocardial changes
result in deficient relaxation and filling but not a reduced EF.
It has previously been shown that increased expression of the ubiquitin ligase WWP1 is
associated with ECM accumulation in HFpEF [19]. Ubiquitination is a post-translational
modification that relies on the sequential action of enzymes, and functions to regulate protein
turnover [14]. It also directs the subcellular localization and function of target proteins, and
target specificity of this process is determined by the E3 ubiquitin ligase [14]. WWP1 is one such
E3 ubiquitin ligase, and it has previously been reported that the expression of Wwp1 in the
heart increases with age [16]. This is important because ECM accumulation and hypertrophy also
increases with age in HFpEF patients, suggesting that WWP1 may have a critical role in HFpEF
development. Not surprisingly, recent studies have demonstrated that the overexpression of
WWP1 is associated with the emergence of LVH and causes no change in the EF of the LV [1].
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When the LV undergoes the myocardial remodeling associated with HFpEF, the LA acts
as an elastic reservoir for modulating the changes in relaxation and filling of the LV [12]. The
positioning of the LA being between the LV and the pulmonary circuit allows it to buffer the
pressure and flow differences. Thus, its dysfunction and remodeling are hallmarks of
established HFpEF [12]. LA dysfunction is an active contributor to the shortness of breath
observed in patients with HF. This is because it causes pulmonary vascular resistance, and
subsequent right ventricular (RV) dysfunction [12]. As LA remodeling continues to compensate
for the changes in the LV, pulmonary hypertension worsens, RV strain is increased, and it can
even cause RV failure [12]. The specific changes in LA observed in patients with HFpEF include
greater LA area and stiffness. Though LA remodeling is observed in both etiologies of HF,
research suggests it causes greater adverse effects in HFpEF patients [12].
Currently the LA area is used as a diagnostic measurement, in that it identifies patients
for hospitalization when enlarged [5]. This is because the LA area has proven to be a reliable
marker for the progression to severe HF [5]. However, there is a need for better measurements
to mark the boundary between when the patient is safe at home and when hospitalization is
needed. One potential marker could involve looking at the implications of the LA dilation rate.
This concept is yet to be studied but holds potential to be a valuable indicator of disease
severity and predictor of clinical outcomes. Therefore, the goal of this study was to determine
whether the rate of LA dilation can be a valuable prognostic tool for animals with early stages
of HFpEF.

7
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Methods
Procedure and Data Collection:
Global Wwp1 deletion was achieved in a group of mice (n=9; Wwp1-/-; Strain B6JNci.CgWwp1tm1Lmat/Mmnc; Stock number 066735-UNC, Mutant Mouse Resource & Research
Centers)10,15,20. At the age of 12 weeks (Baseline), these mice, along with age-matched wild type
mice (n=12, Wwp1+/+), underwent identical transverse aortic banding procedures to produce
LVPO (Figure 1). There were referent control groups of both the Wwp1+/+ and Wwp1-/genotypes that did not undergo the procedure (n=11 and n=14, respectively).
At baseline, echocardiography (40MHz) was performed on every mouse to measure LV
Mass, EF, Doppler Velocities of LV filling (Early-E, late/atrial-A; E/A ratio), LA area, and endsystolic/ diastolic volumes (ESV, EDV). Echocardiography was repeated for all mice at 2 and 4
weeks following LVPO. Once the echocardiographic images were collected, they were analyzed
on Vevolab software to quantify the above parameters of LV function and geometry. The
equation used to calculate the LV mass was (0.8*(1.04*(((LVIDd+IVSd+LVPWd)3-LVIDd3))) +0.6),
where the variables stand for LV interior diameter (LVID), interventricular septum (IVS), LV
posterior wall (LVPW), and diastole (d).
At the conclusion of the 4-week study, all mice underwent a terminal procedure and the
LV of their hearts were harvested. These were snap frozen in liquid nitrogen until polymerase
chain reaction (PCR) testing began. First, each LV sample was cut to ~30mg pieces and RNA was
extracted from them. The concentration and quality of the RNA was then quantified by the
Experion Automated Electrophoresis System. Finally, RNA samples were converted to cDNA and
qualitative real time PCR (qPCR) was used. This biochemical analysis involved quantifying the
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expression of various genes with specific mRNA primers (Table 1), including Wwp1 in the LV of
each mouse.
Data analysis:
Once all echocardiographic measurements and PCR methods were complete, data
analysis began. The four cohorts of mice remained grouped together throughout all statistical
analyses. The echocardiography data was analyzed through use of multiple ANOVAs and t-tests,
which generated statistical differences between the groups. The PCR data was similarly
analyzed and differences in fibrotic gene expression were determined. More specifically, gene
expression was quantified, normalized to a housekeeping gene, and expressed as 2−∆𝐶𝑇 𝑥 100.
The data were summarized in a series of charts and figures.
The LA area data at each time point was averaged for each of the LVPO genotypes and
plotted in Sigmaplot to determine the function of best fit (a 2 parameter III logarithm). To do
so, all functions available in Sigmaplot were matched to fit the averaged data for each
genotype, and the function with the highest R squared value was chosen. After this function
was identified, the LA area measures for each mouse were plotted individually and matched to
that same function to generate an equation for each mouse. Each outputted equation
corresponding to each mouse was in the format of 𝑓(𝑥) = ln(𝑎 + 𝑏𝑥). The variables (values for
a and b) of each of these equations were then averaged in order to generate a comprehensive
model for each genotype. This model represented a predictive regression plot with a 95%
confidence interval.
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Results
Differences between Wwp1+/+ and Wwp1-/-:
Analysis of perioperative and post-surgical mortality revealed differences in survival
between the Wwp1+/+ and Wwp1-/- groups that underwent LVPO induction: Wwp1+/+ had a
significantly greater survival rate during the procedure (69.6% vs. 40.7% in Wwp1-/-), but both
groups had a similar post-surgical survival rate (81.8% vs. 75%, Figure 2). Gene expression
quantification revealed that the expression of Wwp1 in the Wwp1+/+ LVPO group was
significantly greater than that of the Wwp1+/+ no LVPO group (10.4 + 1.4 vs. 5.1 + 0.4, Figure 3).
The levels of Wwp1 expression in the Wwp1-/- groups were not detectable as expected since
exons 10-20 of the Wwp1 gene had been deleted in this strain (Figure 3). The differences in EF
and EDV between the Wwp1+/+ and Wwp1-/- groups prior to the LVPO induction procedure were
not consistent with the phenotypes developed afterwards (namely, differences in severity of
HFpEF between the groups), suggesting negligible predisposition to HFpEF development in
either group (Table 2).
Although at baseline the thickness of the posterior wall of the LV was nearly identical in
the two genotypes, the Wwp1+/+ animals displayed significantly more hypertrophy than the
Wwp1-/- group after 4 weeks of LVPO (Figure 4). LV EF remained stable with LVPO in both
genotypes (59 + 2% vs. 52 + 4%, p >0.05), which is consistent with the HFpEF phenotype. In light
of HFpEF development, indices of LV function and geometry with LVPO were most severe in the
Wwp1+/+ group: LV mass, a measure of hypertrophy, was significantly higher in the Wwp1+/+
animals at the 2-week time point (125.1 + 4.5 vs. 108.2 + 6.7, p<0.05, Table 3). E/A ratio, a
measure of diastolic dysfunction, revealed a nearly identical profile to the differences in LV
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mass at the 4-week time point (3.97 + 0.46 vs. 1.73 + 0.19, p<0.05, Table 3). At the
transcriptional level, expression of pro-fibrotic genes was attenuated in the Wwp1-/- group
compared to that of the Wwp1+/+ group following LVPO induction (Figure 5 and Table 2).
Predictive Regression:
The LA area dilation was significantly greater in the Wwp1+/+ group compared to that of
the Wwp1-/- group during the progression of HFpEF with LVPO in this mouse model (5.69 + 0.02
vs. 4.90 + 0.23, p<0.05, Figure 6A). Surface analysis plots were used to represent the divergence
from the relatively similar baseline values of each of the genotypes. This revealed that LA area
dilation is blunted in Wwp1-/- animals at the 14 and 28-day time points as compared to the
Wwp1+/+ animals at those same time points (Figure 6B). The rate of dilation of the LA was
greatest in the first 0-14 days post LVPO induction in both groups (Figure 6A) compared to the
14-28 day segment. The predictive regression based off of these LA area data was a 2
parameter III logarithmic model with a general equation of 𝑓(𝑥) = ln (𝑎 + 𝑏𝑥) (Figure 7). Here,
the average a and b values were 160.65 and 9.06 for the Wwp1+/+ group, and 83.87 and 3.81 for
the Wwp1-/- group, respectively.

Discussion
This study confirmed that the genetic deletion of the Wwp1 gene alters the progression
of HFpEF with LVPO in a mouse model. More specifically, we saw that the absence of functional
WWP1 protein reduced the development of LVH and subsequent progression to HFpEF. These
conclusions are grounded in the data that reveal a more severe response to the LVPO induction
procedure in Wwp1+/+ mice: a significantly greater LV mass, E/A ratio, LA area, and pro-fibrotic
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gene expression after 4 weeks with LVPO. The quantification of Wwp1 expression confirms the
effectiveness of the Wwp1-/- global knockout, and suggests that WWP1 is normally upregulated
in response to cardiac stress (in this case, LVPO; Figure 4).
The most novel and valuable finding of this study was in the predictive regression
output (Figure 7). The model confirmed the hypothesis that the rate of LA dilation can be a
predictor of severity of HFpEF for mice with the early stages of HFpEF. The equation generated
by the logarithmic model can be used to predict the LA area of a mouse at any future time point
(x). It was crucial that two distinct groups with differing LA dilation profiles (Wwp1+/+ vs. Wwp1/-)

were used to demonstrate that once a mouse can be placed into the correct severity group

(according to the original LA area reading at an early time point), they followed that trajectory
of HF development. This is important because it opens the door to being able to predict the
likelihood of an acute cardiac event at any certain time point according to a human’s trajectory
on their predictive regression. Relating to the initial aims of the study, the model created could
be a prototype of a tool that can determine when hospitalization of HFpEF patients is necessary
according to how well one is following their trajectory. Moreover, since the heart rates of mice
are much greater than that of humans and their rates of atrial filling are much faster, the same
measurements of atrial dilation should be demonstrable in humans. This being said, because
the LVPO induction in mice that was used to create the subjects in this study differs from
natural HFpEF development in humans, the model is not directly translatable and needs
adjusted to compensate for these differences.
Future Directions:
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This ability to model and predict HFpEF severity as a function of rate holds potential to
revolutionize the diagnosis and prognosis of HFpEF in humans. As stated above, the current
methods of using LA area to determine one’s severity of HFpEF falls short in its ability to predict
disease progression. To prove that the prediction model and thus the LA dilation rate
measurements are more valuable than a one-time LA area quantification for patients with early
HFpEF, another study would have to be designed. This would involve taking LA area
measurements more frequently and using each value in the predictive model’s generated
equation to see how close a given patient is following the predicted trajectory.
In terms of barriers to the application to humans, it would be difficult to place people
into trajectory categories (in this study, these were created by the two genotypes) solely on one
LA area measurement. This is because there are many other factors that contribute to one’s
overall risk of developing more severe HFpEF. The factors for humans may include but are not
limited to one’s age, sex, level of activity, diet, BMI, genetic predispositions, and race/ ethnicity.
Therefore, it would be more accurate to create trajectory categories that take these factors into
account at each starting LA area measurement. In order to get the data to solidify these
categories of predictive regressions, another study should be conducted whereby the charts of
diverse HFpEF patients with multiple LA area measurements over time are reviewed and
analyzed for trends. Then a scoring system could be implemented whereby each demographic
and genetic factor has its own scale of severity from 1-5, and a weighted average of these
parameters could be one’s “Final score.” The final score would correlate to the trajectory on
the predictive regression model for any given beginning LA measurement (Figure 8).
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Additionally, the scale of the LA area and the timeline of the progression would have to be
modified to humans according to the values in the chart review.
In addition to the predictive regression model developments described above, it would
also be useful to create relative risk models. Relative risk is the ratio of the probability of an
outcome in an exposed (Ie) vs. non-exposed group (Iu). These models are currently used to
determine the efficacy of a new drug in a clinical trial, as it can take multiple factors into
account [9]. Relevant to this study, the model has the potential to determine the probability of
developing severe LA enlargement (>50% from a baseline measurement). If the outputted ratio
𝐼𝑒

(𝐼𝑢) is: 1- the exposure doesn’t affect the outcome, less than 1- the risk of the outcome is
decreased by the exposure, and greater than 1- the risk of the outcome is increased by the
exposure [17].
The variables being factored into the risk calculation would rely on a series of
echocardiographs to analyze the parameters of LV function and geometry (LV mass/ body
weight ratio, EDV) and indices of diastolic dysfunction (E/A, IVRT, and E’/A’). As demonstrated
in this study, each of these parameters are valuable indicators of HFpEF, and can deviate
drastically between groups with different degrees of severity. To be accounted for in the model,
each of these echocardiographic parameters must be divided into a binary of “severe” or
“normal.” An example of a relative risk model that takes into account multiple factors in
determining the risk for an outcome is included (Figure 9).
Ultimately, relative risk modeling could supply more concrete evidence of the benefits
of using the predictive regression in the prognosis of one’s heart failure progression, as
opposed to just using a one-time measurement of LA area. For instance, the outcome of the
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relative risk model could indicate that patients with severe E/A ratio have 4.6 times greater risk
of LA enlargement (>50%) than patients with a normal E/A ratio (as seen in the right column of
Figure 9). After the above modifications to the predictive regression created in this study, a
patient that is starting to develop HFpEF could have a more accurate prognosis that takes into
account the other parameters of their LV function as well as their family history, race, BMI, age,
sex, level of activity, and diet.
Possible Refutations:
One limitation to this study is its translatability to HFpEF development in humans. Some
might argue that the LVPO induction procedure used to mimic the effects of severe
hypertension and vascular stiffness in humans is much faster, more abrupt, and involves added
stress to the mice in comparison to the natural progression to HFpEF in humans. Given the
substantial difference in the time course of HFpEF development between this study in mice and
the reality in humans, the predictive regression model may need to be adjusted greatly in order
to accurately represent human disease progression. More specifically, the function of best fit
for humans could be different than the 2 parameter III logarithm type used in this study.
WWP1, the ubiquitin E3 ligase studied in this project, has been shown to play a role in
disease progression of cancers, infectious diseases, aging, and neurological diseases due to its
ubiquitous expression in human tissues [21]. It has a high expression in cardiac and skeletal
muscle, and has shown versatility because it has different splice products in different tissues
[13].

There is still ambiguity regarding whether WWP1 is regulated by post-translational

modifications or hormones. Moreover, its role in human immunity is not completely
understood and the mechanism of regulation of WWP1 is yet to be delineated.
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While some studies have shown catastrophic effects in an organism due to genetic
alteration of WWP1, other studies have reported conflicting results where the organism
benefits. For example, in light of cancer development, one study suggests an oncogenic role of
WWP1 in carcinogenesis of the prostate, where overexpression lead to more colony formation
and genetic knockdown lead to suppressed cell proliferation [3,21]. However, another study
reported that cancerous tumors with WWP1 expression had a much better prognosis than
those with low or absent WWP1 expression [8]. One study in C. elegans even found that the
“…deletion of Wwp1 leads to abnormal embryogenesis and a lethal phenotype [7,21].” Before
reaching conclusions, the contexts of each of these studies need to be considered, as WWP1
varies greatly across species and behaves differently under unusual conditions (such as cancer
cells that have undergone genetic changes). Altogether, these studies call for further
investigation about WWP1’s widespread effects in humans.
Although the results of this study suggest that knocking out WWP1 offers protection in
the progression of HFpEF, as confirmed by the differences in the LA Area between the two
genotypes, the mechanism of action and overall effects of global WWP1 deletion are poorly
understood. For example, the Wwp1-/- group had a much lower survival rate during the LVPO
procedure, even though those that survived had a less severe progression of HFpEF afterwards
(Figure 2). One possible explanation of this discrepancy is that WWP1 may have a beneficial
role in an animal’s ability to withstand extreme physical stressors. This would mean that the
Wwp1-/- group interfered with this process, and therefore some of these animals weren’t able
to survive the LVPO induction procedure. It’s important to note that a complete loss of function
of WWP1 (which was used in this study) is not realistic for humans, as therapeutics would only
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decrease the activity of WWP1. Because WWP1 would not be completely removed, the
possibility for some of the negative widespread effects that have been reported in other studies
would be reduced if WWP1 were to become a therapeutic target for mitigating HFpEF
progression in the future.
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Tables and Figures

Gene
Col1a1- collagen, type I, alpha 1
Col1a2- collagen, type I, alpha 2
Col3a1- collagen, type III, alpha 1
Edn1 -endothelin 1
JunB- jun B proto-oncogene
Mmp2- matrix metalloproteinase 2
Mmp9- matrix metalloproteinase 9
Mmp14- matrix metalloproteinase 14
Myc - myelocytomatosis oncogene
Snai1- snail family zinc finger 1
Tgfb1- transforming growth factor, beta 1
Tgfb2- transforming growth factor, beta 2
Timp1- tissue inhibitor of metalloproteinase 1
Vcam1- vascular cell adhesion molecule 1

Wwp1+/+
No-LVPO
(n=11)
3.9 ± 0.5
19.8 ± 2.4
41.4 ± 3.4
0.4 ± 0.0
0.1 ± 0.0
6.4 ± 1.2
0.3 ± 0.0
3.2 ± 0.5
0.2 ± 0.0
0.1 ± 0.0
4.5 ± 0.3
0.5 ± 0.1
0.2 ± 0.0
1.4 ± 0.1

Wwp1-/No-LVPO
(n=13)
4.0 ± 0.4
16.3 ± 0.7
33.8 ± 2.6
0.5 ± 0.1
0.2 ± 0.0
4.7 ± 0.6
0.3 ± 0.0
2.3 ± 0.3
0.2 ± 0.0
0.1 ± 0.0
4.4 ± 0.3
0.5 ± 0.0
0.2 ± 0.0
1.3 ± 0.1

Wwp1+/+
LVPO
(n=10)
11.3 ± 2.1+
37.5 ± 4.5+
49.8 ± 3.8
0.6 ± 0.1+
0.2 ± 0.0
11.6± 2.0+
0.3 ± 0.1
5.1 ± 0.6+
0.5 ± 0.1+
0.2 ± 0.1+
7.3 ± 1.0+
1.2 ± 0.3+
0.8 ± 0.2+
1.8 ± 0.1+

Wwp1-/LVPO
(n=9)
4.7 ± 0.6*
22.8 ± 1.9*
46.0 ± 2.7+
0.4 ± 0.0*
0.2 ± 0.1
6.6 ± 1.5*
0.2 ± 0.0
3.2 ± 0.4*
0.3 ± 0.1*
0.1 ± 0.0*
5.3 ± 0.5*
0.7 ± 0.1*
0.3 ± 0.0*
1.2 ± 0.1*

* p<0.05 vs. Wwp1+/+ LVPO
+ p<0.05 vs respective no-LVPO
All values shown are 2(-ΔCt) *100
Table 1. A comprehensive list of relevant genes with varying expression as a function of
genotype. All data reflects expression in the tissue collected from extermination of animals at
the 28-day time point. Results expressed as 2(-ΔCt) *100 +/- mean, and an ANOVA was run to
determine significance (p<0.05).
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Wwp1+/+

Wwp1-/-

Heart Rate (bpm)

399 ± 7

391 ± 8

Ejection Fraction (%)

66 ± 1*

58 ± 1

End Diastolic Volume (µL)

59 ± 2*

65 ± 2

Mass (mg)

83 ± 3

89 ± 3

34

41

(n)

* = p<0.05 vs. Wwp1-/Table 2. Differences in LV function between Wwp1+/+ and Wwp1-/- prior to LVPO induction
procedure. The Wwp1+/+ group started the study with a lower LV mass and EDV compared to
the Wwp1-/- group.
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Treatment
& Time
point
Baseline
No LVPO
Day 14
LVPO
Day 14
No LVPO
Day 28
LVPO
Day 28
Baseline
No LVPO
Day 14
LVPO
Day 14
No LVPO
Day 28
LVPO
Day 28

EF (%)

EDV (µL) LV Mass (mg)

E/A

LA Area
(mm2)

65 ± 2

59 ± 3

82.9 ± 2.1

1.86 ± 0.11

4.52 ± 0.16

64 ± 3

57 ± 3

86.7 ± 4.5

2.01 ± 0.17

4.73 ± 0.22

62 ± 4

51 ±4

125.1 ± 4.5 *

2.65 ± 0.35 *

5.66 ± 0.23 *

65 ± 2

59 ± 2

90.2 ± 3.3

1.92 ± 0.14

4.92 ± 0.15

59 ± 2 *

59 ± 4

138.4 ± 9.0 *

3.97 ± 0.46 *#

5.69 ± 0.20 *

56 ± 2 +

65 ± 3

91.1 ± 3.5 +

1.74 ± 0.10

4.52 ± 0.16

61 ± 3

58 ± 3

87.0 ± 4.5

1.83 ± 0.16

4.72 ± 0.12

58 ± 4

57 ± 5

108.2 ± 6.7 * +

2.34 ± 0.31 *

4.86 ± 0.28 +

55 ± 2 + #

62 ± 3

90.9 ± 4.3

1.87 ± 0.14

4.52 ± 0.12 +

52 ± 4

64 ± 6

122.1 ± 9.5 *

1.73 ± 0.19 +

4.90 ± 0.23 +

EF = Ejection Fraction

* p<0.05 vs. Respective Baseline Value

Wwp1+/+ No LVPO n=11

EDV= End Diastolic Volume

+ p<0.05 vs. Time Matched Wwp1+/+

Wwp1+/+ LVPO n=12

LV= Left Ventricle

# p<0.05 vs. Respective Day 14 Value

Wwp1-/- No LVPO n=14

E/A= Doppler velocities:
early/late-atrial

Wwp1-/- LVPO n=9

LA= Left Atrium

Table 3. The effects of Wwp1 deletion on LV function and geometry. Following LVPO, EF
remained consistent while significant differences between the two genotypes emerged for LV
mass, E/A ratio, and LA Area.
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Figure 1. Animation of the Left Ventricular Pressure Overload (LVPO) induction procedure and a
timeline representing of the methods used in the study.

Intra-Operative Mortality

Post-Surgical Survival
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16/23
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p<0.01
11/27
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0.8

Days
Wwp1+/+ Sham (n=11)
Wwp1+/+ TAC (n=23)
Wwp1-/- Sham (n=14)
Wwp1-/- TAC (n=27)

1.0

Percent survival

Percent survival

100

9/11
12/16

80
60
40
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0
1

4

8
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16

20

24

Days
Wwp1+/+ Sham (n=11)
Wwp1+/+ TAC (n=16)
Wwp1-/- Sham (n=14)
Wwp1-/- TAC (n=11)

Figure 2. Intra-operative and post-surgical mortality for all groups in the study.
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Relative Quantification of Wwp1
20

+

18
16

(2^(-ΔCt)*100)

14
12
10
8
6
4
2

ND

ND

No LVPO

LVPO

0

No LVPO

LVPO
Wwp1+/+
Wwp1-/-

* p<0.05 vs. Wwp1+/+
+ p<0.05 vs. respective Non-LVPO

Figure 3. WWP1 expression in all groups. Levels were non-detectable in Wwp1-/- groups, and
there was a significant difference in expression between the Wwp1+/+ no LVPO and Wwp1+/+
LVPO groups. The error bars represent the standard error.
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Figure 4. Although at baseline the thickness of the posterior wall of the LV was nearly identical in
the two groups, after 4 weeks of LVPO, the Wwp1+/+ animals displayed significantly more
hypertrophy than the Wwp1-/- mice.
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% Change in Relative Copy Number
* = p<0.05 vs. 0

Wwp1

+/+

LVPO

-/-

Wwp1 LVPO

Figure 5. At the transcriptional level, expression of pro-fibrotic genes were attenuated in the
Wwp1-/- compared to the Wwp1+/+ following LVPO induction procedure as assessed by qPCR.
The error bars represent the standard error.
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6A.
LA Area LVPO Means

3
5.5

*

*

2

+

+

LA Area
(mm^2)

LA Area (mm^2)

LA Area Absolute Change from Baseline

4

6.0

5.0

1

7

0

4.5
6

4.0

-1

5

Baseline

6B.

14
Day

-2

28

14
Days

4
3

Wwp1+/+ LVPO
Wwp1-/- LVPO 2

Day

* = p<0.05 vs. Respective Baseline Value (0)
+/+

+= p<0.05 vs. Respective Wwp1

Time Point

1

1
2
3
4
5
6
7

Figure 6. A. Differences in LA area during the progression of HFpEF in LVPO groups. The rate of
LA area dilation was greatest in the first 14 days of the study. LA area dilation was significantly
reduced in the Wwp1-/- mice compared to the Wwp1+/+ mice. B. Surface analysis plots
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representing the LA area values for each mouse in the LVPO groups. Both the Wwp1+/+ and
Wwp1-/- groups had similar baseline values, but the LA area dilation is blunted in the Wwp1-/group at the 14 and 28-day time points.

Wwp1+/+ LVPO
Wwp1-/- LVPO

Figure 7. The predictive regression analysis representing the projection of HFpEF as a function
of baseline LA area measurement and genotype. Animals in the Wwp1+/+ group follow the blue
projection, and those in the Wwp1-/- group follow the red projection if their starting LA area
measurements are within the bounds of the 95% confidence interval (CI).

Snyder, L

31

6.5

2

LA Area (mm )

6.0

5.5

5.0

4.5

4.0
0
Score 1
Score 2
Score 3
Score 4
Score 5

3

6

9

12

15

18

Time (months)

Figure 8. An example of a predictive regression with trajectory categories. The scores in the
legend represent one’s final score after taking demographic factors into account. The x- axis has
been modified to represent a possible human time scale for HFpEF progression.
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Figure 9. An example of a relative risk model, including the factors on the left side, the actual
model in the middle, and the output on the right side. Retrieved from:

Chu, C. J., Johnston, R. L., Buscombe, C., Sallam, A. B.,… Yang, Y.C. (2016). Risk Factors and
Incidence of Macular Edema After Cataract Surgery: A Database Study of 81984 Eyes.
Opthamology, 123(2):316-23. doi: 10.1016/j.ophtha.2015.10.001
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